Market Runner: Dimension Therapeutics Inc Can’t Burn Your Short Portfolio. Just Reaches 52-Week Low

Market Runner: Dimension Therapeutics Inc Can't Burn Your Short Portfolio. Just Reaches 52 Week Low

The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) hit a new 52-week low and has $4.35 target or 13.00% below today’s $5.00 share price. The 8 months bearish chart indicates high risk for the $125.15M company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $4.35 price target is reached, the company will be worth $16.27 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 16,869 shares traded hands. Dimension Therapeutics Inc (NASDAQ:DMTX) has declined 36.78% since March 31, 2016 and is downtrending. It has underperformed by 39.31% the S&P500.

Analysts await Dimension Therapeutics Inc (NASDAQ:DMTX) to report earnings on December, 2. They expect $-0.50 EPS, up 81.68% or $2.23 from last year’s $-2.73 per share. After $-0.49 actual EPS reported by Dimension Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.04% negative EPS growth.

Dimension Therapeutics Inc (NASDAQ:DMTX) Ratings Coverage

Out of 5 analysts covering Dimension Therapeutics (NASDAQ:DMTX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dimension Therapeutics has been the topic of 9 analyst reports since November 6, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald initiated Dimension Therapeutics Inc (NASDAQ:DMTX) rating on Friday, June 3. Cantor Fitzgerald has “Buy” rating and $32 price target. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. The rating was initiated by Roth Capital on Friday, November 6 with “Buy”. As per Monday, November 16, the company rating was initiated by Citigroup. The firm has “Buy” rating given on Thursday, February 18 by Cantor Fitzgerald. The firm earned “Buy” rating on Monday, November 16 by Goldman Sachs. As per Friday, December 4, the company rating was initiated by Goldman Sachs. The firm earned “Buy” rating on Monday, November 16 by Canaccord Genuity.

According to Zacks Investment Research, “Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.”

More important recent Dimension Therapeutics Inc (NASDAQ:DMTX) news were published by: Wsj.com which released: “In Latest Setback for Biotech IPOs, Dimension Therapeutics Shares Fall in Debut” on October 22, 2015, also Marketwatch.com published article titled: “Dimension Therapeutics Inc.”, Businesswire.com published: “Dimension Therapeutics Secures $65 Million in Oversubscribed Series B Financing” on April 21, 2015. More interesting news about Dimension Therapeutics Inc (NASDAQ:DMTX) was released by: Globenewswire.com and their article: “Dimension Therapeutics Announces Preclinical Data from Bayer-Partnered …” with publication date: May 07, 2016.

DMTX Company Profile

Dimension Therapeutics, Inc., incorporated on June 20, 2013, is a gene therapy company. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The Firm has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV) vector delivery technology. The Firm uses mammalian cells in its manufacturing approach for its AAV product candidates. The Company’s AAV manufacturing is performed in over two mammalian cell types, human embryonic kidney 293 cells (HEK293 cells) and HeLa cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment